Fibrinolytic therapy is an effective treatment for stroke patients and the therapeutic window for intravenous tissue-type plasminogen activator therapy is 3–4.5 h from the onset of the first symptoms; however, only about 25% of patients on the ward receive thrombolytic treatment within the indicated time window24,25. The gene discussed is PLAT; the disease is stroke disorder.